ARTICLE: Evaluation and Management of Patients With Stable Angina: Beyond the Ischemia Paradigm
AUTHORS: Richard Ferraro, Jacqueline M. Latina, Abdulhamied Alfaddagh, Erin D. Michos, Michael J. Blaha, Steven R. Jones, Garima Sharma, Jeffrey C. Trost, William E. Boden, William S. Weintraub, João A.C. Lima, Roger S. Blumenthal, Valentin Fuster, Armin Arbab-Zadeh
JOURNAL: J Am Coll Cardiol. 2020 Nov 10;76(19):2252-2266. doi: 10.1016/j.jacc.2020.08.078.
Coronary heart disease is a chronic, systemic disease with a wide range of associated symptoms, clinical outcomes, and health care expenditure. Adverse events from coronary heart disease can be mitigated or avoided with lifestyle and risk factor modifications, and medical therapy. These measures are effective in slowing the progression of atherosclerotic disease and in reducing the risk of thrombosis in the setting of plaque disruptions. With increasing effectiveness of prevention and medical therapy, the role of coronary artery revascularization has decreased and is largely confined to subgroups of patients with unacceptable angina, severe left ventricular systolic dysfunction, or high-risk coronary anatomy. There is a compelling need to allocate resources appropriately to improve prevention. Herein, we review the scientific evidence in support of medical therapy and revascularization for the management of patients with stable coronary heart disease and discuss implications for the evaluation of patients with stable angina and public policy.
For the full article, click here.
For a link to the abstract, click here.